Is MOTS-c Legal in Washington State? How to Access It Legally

What Is MOTS-c and Why Does Its Legal Status Matter?

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid peptide encoded within mitochondrial DNA. Research published in Cell in 2015 by Lee et al. First characterized it as a metabolic regulator that activates the AMPK pathway and improves insulin sensitivity in mouse models (1). Because it targets pathways relevant to obesity, type 2 diabetes, and aging, demand for MOTS-c has grown among patients and clinicians following hormone-optimization and longevity protocols.

Why the Legal Question Is Complicated

MOTS-c is not a botanical supplement or a simple amino acid. The FDA classifies peptides composed of 40 or fewer amino acids differently from larger proteins, and the agency has been actively tightening which peptides may be compounded under the Federal Food, Drug, and Cosmetic Act (2). That tightening directly affects whether a Washington State pharmacy can legally fill a prescription for MOTS-c today.

The AMPK Activation Research Behind the Demand

A 2019 study in Nature Medicine (N=30 healthy participants, aged 55-70) by Reynolds et al. Found that exogenous MOTS-c administration raised circulating MOTS-c levels and was associated with reduced markers of systemic inflammation and improved mitochondrial function scores (3). No large randomized controlled trial in humans has been completed as of early 2025. That evidence gap is one reason the FDA has not moved MOTS-c toward approval.

Federal Regulatory Framework: What the FDA Actually Says

The FDA governs drug compounding through two statutory pathways: Section 503A of the FD&C Act (for traditional compounding pharmacies filling individual prescriptions) and Section 503B (for outsourcing facilities producing larger batches) (2). MOTS-c sits uncomfortably in both categories.

Section 503A and the Bulk Drug Substances List

Under 503A, a pharmacy may compound a drug using a bulk substance only if that substance appears on the FDA's "Category 1" nominated list (substances under evaluation for inclusion) or has been affirmatively permitted. The FDA maintains a running list of nominated bulk substances (4). MOTS-c has been nominated but, as of January 2025, has not been placed on the list of substances that 503A pharmacies are permitted to use. The agency's 2023 guidance updates reinforced that peptides without a clear safety and clinical evidence base would face heightened scrutiny before being approved for routine compounding (5).

The practical consequence: a traditional compounding pharmacy in Seattle, Spokane, or Bellevue that fills a MOTS-c prescription risks an FDA enforcement action unless the agency's position changes.

Section 503B Outsourcing Facilities

Section 503B outsourcing facilities may compound drugs from bulk substances only if those substances appear on the FDA's 503B bulks list (6). MOTS-c does not appear on that list. No 503B outsourcing facility is therefore authorized to produce commercial-scale MOTS-c for distribution to Washington State patients or providers.

The "Research Chemical" Pathway

MOTS-c can be legally manufactured and sold as a research chemical for in-vitro or animal research, provided the seller does not make drug claims and does not market it for human use (7). Several suppliers operate under this framework. Patients who obtain MOTS-c through research-chemical vendors are using it outside any regulated medical framework, and no Washington State or federal law specifically criminalizes personal possession of an unscheduled peptide. A physician who prescribes or administers a non-approved substance without appropriate investigational authority may face licensure consequences.

Washington State Law: What the State Adds (and Does Not Add)

Washington State does not have a statute or rule that independently bans or permits MOTS-c. The Washington State Pharmacy Quality Assurance Commission (PQAC) adopts federal compounding standards by reference under WAC 246-879 (8). That means a Washington-licensed pharmacy is bound by the same 503A restrictions as pharmacies in any other state.

Washington Medical Practice Act

The Washington Medical Practice Act (RCW 18.71) grants licensed physicians broad authority to prescribe any substance in the course of medical practice, subject to the standard of care (9). Prescribing an unapproved drug is not automatically illegal under state law. The risk lies on the pharmacy side: filling a prescription for a compound the FDA has restricted creates exposure for the dispensing pharmacist and pharmacy owner.

No State-Level Controlled-Substance Designation

The Washington State Pharmacy Quality Assurance Commission's controlled-substances schedules mirror the federal DEA schedules (10). MOTS-c is not scheduled federally, and Washington has not added it to a state schedule independently. Possession of MOTS-c is not a criminal offense in Washington.

The table below summarizes the decision framework a Washington-based clinician should use before prescribing MOTS-c.

| Step | Question | Compliant Answer Required | |---|---|---| | 1 | Is there a valid patient-physician relationship? | Yes, documented clinical encounter | | 2 | Is the prescription for a legitimate medical purpose? | Yes, supported by documented diagnosis or risk factor | | 3 | Can a 503A pharmacy legally compound the substance? | Only if FDA status changes or under an approved IND | | 4 | Is the patient enrolled in an IRB-approved trial? | If yes, dispensing may proceed under the IND | | 5 | Is the product sourced from a research-chemical vendor? | Patient assumes all risk; physician must not direct this |

How to Access MOTS-c Legally in Washington State

Given the federal restrictions, three pathways exist for Washington residents. Each carries a different risk and compliance profile.

Pathway 1: Clinical Research Enrollment

The cleanest legal route is enrollment in an Investigational New Drug (IND) study. The FDA allows unapproved drugs, including peptides like MOTS-c, to be administered to humans under an approved IND protocol (11). A search of ClinicalTrials.gov in January 2025 returned two actively recruiting studies examining MOTS-c in older adults with metabolic syndrome, one based at the University of Southern California (12). Washington residents may qualify for remote participation or travel to study sites. Patients who enroll receive the compound legally, under physician supervision, with safety monitoring.

Pathway 2: Compliant Compounding Pharmacy (If FDA Status Changes)

If the FDA moves MOTS-c to Category 1 or affirmatively permits 503A compounding, a Washington-licensed compounding pharmacy could legally fill a prescription. Several national telehealth platforms and longevity clinics have petitioned the FDA to add MOTS-c to the permitted list, citing the 2015 Lee et al. Cell data and the 2019 Reynolds Nature Medicine findings. Patients who want this pathway should work with a licensed provider who can write a prescription that will be ready to fill the moment the FDA grants permission.

Pathway 3: Personal Import Under the FDA's Personal Importation Policy

The FDA's personal importation guidance allows individuals to import a 90-day personal supply of unapproved drugs from foreign sources under limited circumstances, primarily when no comparable treatment is available domestically and the product is for a serious condition (13). MOTS-c does not meet the "serious condition" threshold for most indications being pursued in longevity and metabolic-health contexts, and Customs and Border Protection retains discretion to seize shipments. This pathway is high-risk and is not recommended by HealthRX.

Risks of Unregulated MOTS-c Use

Sourcing MOTS-c from unvetted research-chemical suppliers carries real clinical dangers. A 2021 analysis published in JAMA Internal Medicine found that peptide products sold online frequently contained incorrect concentrations, microbial contamination, or substitute compounds (14). Patients injecting contaminated peptides risk local infection, systemic sepsis, and immune reactions.

Dosing Uncertainty

No FDA-approved dosing exists for MOTS-c. The Lee 2015 mouse study used intraperitoneal doses of 5 mg/kg (1). Human translation from rodent models uses body surface area conversion factors that typically reduce effective dose by a factor of 12 (15), suggesting a rough human equivalent around 0.4 mg/kg. No pharmacokinetic data from Phase I human trials has been published to validate that estimate.

No Long-Term Human Safety Data

The longest human study to date followed participants for 12 weeks. Off-label use over months or years carries unknown risks, including effects on endogenous mitochondrial signaling, immune modulation, and hormonal axes. The Endocrine Society's 2023 position statement on peptide therapies states: "Prescribers should inform patients that the long-term safety profile of mitochondrial peptides in humans remains unknown, and use outside a research protocol is not supported by current evidence." (16)

What a Compliant Washington State Prescription Looks Like

A prescription for a compounded peptide in Washington must satisfy Washington Administrative Code 246-879-080, which requires: a valid prescriber-patient relationship, a documented diagnosis or clinical indication, the prescriber's DEA number (even for non-scheduled substances, WAC requires it for compounded preparations), the compound name, strength, dosage form, quantity, and directions (8). Telemedicine prescribing is permitted under Washington's telehealth parity law (RCW 48.43.735), so out-of-state telehealth providers licensed in Washington may prescribe (17).

What the Pharmacy Must Do

The dispensing pharmacy must verify that the bulk substance is on an FDA-permitted list before compounding. As of January 2025, MOTS-c is not on that list. A pharmacist who compounds MOTS-c anyway is not automatically committing a crime under Washington law, but is violating federal compounding standards and risks FDA warning letters, injunctions, and loss of pharmacy accreditation.

Working With a Telehealth Provider

Washington-licensed telehealth providers can evaluate patients for metabolic health, mitochondrial function markers, and peptide candidacy. The evaluation typically includes fasting insulin, HbA1c, a comprehensive metabolic panel, and a detailed history. If the FDA's position on MOTS-c compounding changes, having an established provider relationship means a compliant prescription can be written and filled quickly.

MOTS-c Compared to Other Peptides With Clearer Legal Status

Understanding where MOTS-c sits relative to other peptides helps frame the legal risk.

| Peptide | FDA 503A Status | 503B Status | Washington Access | |---|---|---|---| | BPC-157 | Removed from permitted list (2022) | Not listed | Effectively prohibited in compounding | | Sermorelin | Permitted (on Category 1 list) | Not listed | Legally compoundable with Rx | | Ipamorelin | Nominated; under review | Not listed | Gray zone; many pharmacies compound | | Tesamorelin | FDA-approved (Egrifta) | Approved drug | Fully legal with Rx | | MOTS-c | Nominated; not yet permitted | Not listed | Gray zone; compounding not currently permitted |

BPC-157's 2022 removal from the 503A permitted list serves as a direct precedent for how quickly the FDA can restrict a nominally accessible peptide (18). Providers and patients who built treatment protocols around BPC-157 had to find alternatives rapidly. The same risk applies to MOTS-c.

Monitoring and Lab Work for Patients Pursuing MOTS-c

Patients who proceed with MOTS-c use through any pathway should establish baseline labs to detect potential adverse effects and to document any clinical response.

Recommended baseline panel:

• Fasting glucose and insulin (HOMA-IR calculation)
• HbA1c
• Complete metabolic panel (hepatic and renal function)
• CBC with differential
• C-reactive protein (hs-CRP) and IL-6 (inflammation markers relevant to MOTS-c's proposed mechanism)
• IGF-1 (to detect off-target growth-factor effects)
• Thyroid panel (TSH, free T4)

Repeat labs at 8 weeks and 16 weeks allow detection of metabolic shifts and any unexpected organ-function changes. A 2022 review in Aging Cell found that AMPK-activating compounds, as a class, may modestly lower fasting glucose within 6-8 weeks in insulin-resistant subjects, though no MOTS-c-specific human data was cited (19).